Clinical trials: Hematological Neoplasm
Multiple Myeloma, Hematologic Malignancies
A Study of BL-M24D1 in Patients With Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies
This study is an open, multicenter, non-randomized phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics characteristics and preliminary efficacy of BL-M24D1 in patients with relapsed or refractory…
- Trial name
- NCT07255898
- Testing
- BL-M24D1
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Polycythemia Vera
Observational Study on the Use of Ropeginterferon Alfa-2b in Polycythemia Vera (ROPEG-PV)
Polycythaemia vera (PV) is associated with a reduced quality of life, a high rate of vascular events, and an intrinsic risk of disease evolution.
- Trial name
- NCT06506084
- Testing
- Ropeginterferon alfa-2b
- Where
- 37 sites in Italy, Poland
- Volunteers
- 429 people
- Sponsor
- FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
Streptococcal Sepsis, Hematologic Malignancies
Trial of Prophylactic Versus Empirical Vancomycin for the Prevention of Streptococcal Sepsis After Hematopoietic Cell Transplantation
This is a randomized 2-arm study to compare two different times of giving the drug vancomycin. Half of the patients will begin vancomycin two days before a bone marrow transplant.
- Trial name
- NCT00138112
- Testing
- Empirical Vancomycin, Prophylactic Vancomycin
- Where
- United States
- Volunteers
- 126 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Comparing Brief Behavioral Therapy (BBT-CI) and Healthy Eating Education Learning (HEAL) for Cancer-Related Sleep Problems While Receiving Cancer Treatment
This phase III trial compares BBT-CI to HEAL for the reduction of insomnia in patients with stage I-IV cancer who are receiving cancer treatment. Cancer treatment can cause side effects such as sleep problems.
- Trial name
- BBT-II (NCT04829539)
- Testing
- Behavioral Intervention, Electronic Health Record Review, Quality-of-Life Assessment
- Where
- 153 sites in United States
- Volunteers
- 400 people
- Sponsor
- University of Rochester NCORP Research Base
NHL, Multiple Myeloma
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
This is an open label, Phase 1/2, first-in-human, multiple ascending dose, and dose-expansion study of IDP-023 administered as a single agent and in combination with or without interleukin-2 (IL-2), and with or without…
- Conditions
- NHL, Multiple Myeloma, Blood Cancer, Refractory Non-Hodgkin Lymphoma
- Trial name
- NCT06119685
- Testing
- IDP-023, Rituximab, Daratumumab
- Where
- 12 sites in United States
- Volunteers
- 128 people
- Sponsor
- Indapta Therapeutics, INC.
Solid Tumors, Hematologic Neoplasms
Allogeneic Hematopoietic Stem Cell Transplantation
To assess the engraftment of hematopoietic stem cells following reduced-intensity conditioning in children presenting with solid tumors or hematological malignancy by evaluating post-transplantation chimerism and hematological…
- Trial name
- RICE (NCT00750126)
- Testing
- Fludarabine, Busulfan, Thymoglobulin
- Where
- France
- Volunteers
- 30 people
- Sponsor
- University Hospital, Clermont-Ferrand
Polycythemia Vera
Changes in QoL and Symptoms in Patients With Polycythemia Vera Receiving Ruxo in a Routine Clinical Practice
The purpose of this multicenter observational prospective cohort study is to examine changes in QoL and symptoms in patients with polycythemia vera (PV) during treatment with ruxolitinib (Ruxo), and to evaluate efficacy and…
- Trial name
- QoL-PV-R (NCT05566535)
- Testing
- Ruxolitinib
- Volunteers
- 32 people
- Sponsor
- Multinational Center for Quality of Life Research, Russia
B Cell Lymphoma, Acute Lymphoblastic Leukemia
Efficacy and Safety of CD19-CAR.p40-T in Patients With Relapsed/Refractory CD19-Positive Hematologic Malignancies
1. Study Title: A Study on the Efficacy and safety of Autocrine p40-Expressing CD19-Targeted Chimeric Antigen Receptor T Cells (CD19-CAR.p40-T) in Patients With Relapsed/Refractory CD19-Positive Hematologic Malignancies 2.
- Conditions
- B Cell Lymphoma, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
- Trial name
- CAR-p40-T (NCT07584889)
- Testing
- CAR-T cell
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Shenzhen University General Hospital
Constitutional Mismatch Repair Deficiency Syndrome, Hematopoietic and Lymphoid Cell Neoplasm
Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study
This phase Ib trial investigates the side effects of the combination of nivolumab and ipilimumab, and to see how well they work in treating patients with cancers that have come back (relapsed) or does not respond to treatment…
- Conditions
- Constitutional Mismatch Repair Deficiency Syndrome, Hematopoietic and Lymphoid Cell Neoplasm, Lynch Syndrome, Recurrent Lymphoma
- Trial name
- NCT04500548
- Testing
- Biospecimen Collection, Ipilimumab, Nivolumab
- Where
- 9 sites in United States, Canada
- Sponsor
- National Cancer Institute (NCI)
Hematological Malignancies
A Phase I, Single-Arm, Open-Label Clinical Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of CHT101 Injection in Subjects With Relapsed/Refractory T-Cell and B-Cell Hematological Malignancies
Primary Objective: To evaluate the safety, tolerability, and dose-limiting toxicity of CD70-targeted chimeric antigen receptor allogeneic T-cell injection (CHT101) in the treatment of subjects with CD70-positive…
- Trial name
- NCT07809126
- Testing
- CD70-targeted chimeric antigen receptor allogeneic T-cell injection (CHT101)
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Nanjing Miracle Biotechnology Co., Ltd.
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing AZD4547 as a Potential Targeted Treatment in Cancers With FGFR Genetic Changes (MATCH-Subprotocol W)
This phase II MATCH treatment trial identifies the effects of AZD4547 in patients whose cancer has genetic changes called FGFR gene alterations.
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma
- Trial name
- NCT04439240
- Testing
- FGFR Inhibitor AZD4547
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- National Cancer Institute (NCI)
Hematologic Malignancy
Prospective Cohort With Hemopathy in Languedoc-Roussillon
Prospective Cohort Study of clinical and laboratory data of patients with hemopathy.
- Trial name
- HemoDiag (NCT02134574)
- Testing
- hematologic malignancy
- Where
- France
- Volunteers
- 500 people
- Sponsor
- University Hospital, Montpellier
Acute Lymphoblastic Leukemia, Non-Hodgkin's Lymphoma
A Study of CT-RD06 Cell Injection in Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancy
A study of CT-RD06 cell injection in patients with relapsed or refractory CD19+ B-cell hematological malignancy.
- Trial name
- NCT04226989
- Testing
- CT-RD06
- Where
- China
- Volunteers
- 72 people
- Sponsor
- He Huang
Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia in Remission
Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematological Cancer Who Are Undergoing Umbilical Cord Blood Transplant
This phase II trial studies how well giving treosulfan together with fludarabine phosphate and total-body irradiation (TBI) works in treating patients with hematological cancer who are undergoing umbilical cord blood transplant…
- Conditions
- Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia in Remission, Blasts Under 5 Percent of Bone Marrow Nucleated Cells
- Trial name
- NCT00796068
- Testing
- Cyclosporine, Fludarabine Phosphate, Laboratory Biomarker Analysis
- Where
- 3 sites in United States
- Volunteers
- 130 people
- Sponsor
- Fred Hutchinson Cancer Center
Leukemia, Myeloma
HEME Home Transfusion Program
This research study is evaluating whether a new care delivery program that provides access to home blood transfusions in hospice (i.e, HEME-Hospice) compared to regular standard of care improves quality of life, mood, and…
- Conditions
- Leukemia, Myeloma, Myelodysplastic Syndromes, Hematologic Malignancy
- Trial name
- NCT06487247
- Testing
- HEME-Hospice Program
- Where
- 2 sites in United States
- Volunteers
- 700 people
- Sponsor
- Dana-Farber Cancer Institute
Hematologic Malignancy, Caregiver
A Positive Psychology Based Intervention (PATH-C) for Caregivers of HSCT Survivors
The goal of this randomized clinical trial is to evaluate whether a positive psychology intervention (PATH-C) can improve psychological well-being, quality of life, and physical activity in caregivers of patients undergoing…
- Trial name
- PATH-C (NCT06153797)
- Testing
- PATH-C
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Brigham and Women's Hospital
Irradiated Bone Marrow, Transplant-Related Hematologic Malignancy
Treosulfan-TMI Conditioning and Rapamycin GvHD Prophylaxis Before Allo-HSCT
TrRaMM-TMI is a phase I trial to evaluate the feasibility and efficacy of an original sequential TMI/TrRaMM (Total Marrow Irradiation/Treosulfan-Rapamycin-Mycophenolate Mofetil) schedule in patients with hematological…
- Conditions
- Irradiated Bone Marrow, Transplant-Related Hematologic Malignancy, Leukemia, Acute, Multiple Myeloma
- Trial name
- TrRaMM-TMI (NCT03963024)
- Testing
- Conditioning treatment "Treosulfan-TMI", SCT, GvHD prophylaxis
- Where
- Italy
- Volunteers
- 9 people
- Sponsor
- IRCCS San Raffaele
Haematological Malignancy, Bone Marrow Transplant Complications
Nutrition and Metabolic Prehabilitation in HSCT Patients UK and ROI. BSBMT Multi-centre Survey.
To explore current practices of nutrition and metabolic screening, assessment and management prior to Haematopoietic Stem Cell Transplant (HSCT) in UK and ROI transplant centres.
- Conditions
- Haematological Malignancy, Bone Marrow Transplant Complications, Stem Cell Transplant Complications, Nutrition Aspect of Cancer
- Trial name
- NCT05352789
- Testing
- Non validated Survey
- Where
- United Kingdom
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Nottingham University Hospitals NHS Trust
Graft Versus Host Disease, Hematologic Neoplasms
Optimizing PTCy Dose and Timing
Background: Stem cell or bone marrow transplants can cure or control blood cancers. Sometimes the donor cells see the recipient's body as foreign. This can cause complications.
- Trial name
- NCT03983850
- Testing
- Busulfan, Fludarabine, Cyclophosphamide
- Where
- United States
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Hematologic Neoplasms
Feasibility Study of Genomic Sequencing to Find Potential Targets for Personalized Therapy
This study is aimed to determine the feasibility of obtaining and molecularly characterizing pre-treatment tumor biopsies, to determine the feasibility of obtaining and molecularly characterizing archival and post-treatment tumor…
- Trial name
- NCT01869218
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Colorado, Denver
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.